Live Attenuated RSV Vaccines Based on Codon-Pair Deoptimization
The technology includes patent rights and related materials for live attenuated viruses that can be used as a prophylactic vaccine against respiratory syncytial virus. The viruses are generated using codon-pair deoptimization techniques, resulting in attenuation based on hundreds or thousands of nucleotide substitutions with no differences at the amino acid level. Various permutations are based on deoptimization of the RSV polymerase ORF, the F and G glycoprotein ORFs, the NS1, NS2, N, P, M, and SH ORFs, or all of these in combination. Experimental growth data for representative viruses in mice and in African Green Monkeys demonstrated in vivo growth attenuation.
|Potential Commercial Applications:||Competitive Advantages:||
Peter Collins (NIAID)
Cyril Le Nouen (NIAID)
Linda Brock (NIAID)
Ursula Buchholz (NIAID)
Joshua DiNapoli (NIAID)
US Application No. 61/762,768
US Application No. 61/794,155
Collins PL, Melero JA. PMID 21963675
Coleman JR, et al. PMID 18583614
Michael Shmilovich , Esq.
NIH Office of Technology Transfer
OTT Reference No: E-080-2013/0